S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
15 A.I. Trading Opportunities a Day (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Constellation Brands Taps into Growth: Analysts Bullish on Stock
15 A.I. Trading Opportunities a Day (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
15 A.I. Trading Opportunities a Day (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Constellation Brands Taps into Growth: Analysts Bullish on Stock
15 A.I. Trading Opportunities a Day (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
15 A.I. Trading Opportunities a Day (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Constellation Brands Taps into Growth: Analysts Bullish on Stock
15 A.I. Trading Opportunities a Day (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
15 A.I. Trading Opportunities a Day (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Constellation Brands Taps into Growth: Analysts Bullish on Stock
15 A.I. Trading Opportunities a Day (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:SLS

SELLAS Life Sciences Group (SLS) Stock Forecast, Price & News

$1.71
+0.02 (+1.18%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.65
▼
$1.71
50-Day Range
$1.39
▼
$6.15
52-Week Range
$1.17
▼
$5.58
Volume
112,397 shs
Average Volume
171,520 shs
Market Capitalization
$48.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

SELLAS Life Sciences Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
309.4% Upside
$7.00 Price Target
Short Interest
Healthy
4.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

766th out of 983 stocks

Pharmaceutical Preparations Industry

385th out of 486 stocks

See Top Rated MarketRank™ Stocks Here

SLS stock logo

About SELLAS Life Sciences Group (NASDAQ:SLS) Stock

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

SLS Stock News Headlines

May 25, 2023 | finance.yahoo.com
SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
May 16, 2023 | finance.yahoo.com
SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia
June 3, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
May 14, 2023 | americanbankingnews.com
Solaris Resources (CVE:SLS) Trading Down 2.7%
May 12, 2023 | finanznachrichten.de
SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
May 11, 2023 | msn.com
Unusual Call Option Trade in SELLAS Life Sciences Group (SLS) Worth $37.03K
May 11, 2023 | finance.yahoo.com
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
May 5, 2023 | markets.businessinsider.com
SELLAS Life Sciences Group (SLS) Receives a Buy from Maxim Group
June 3, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
May 4, 2023 | finance.yahoo.com
SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study
April 26, 2023 | finance.yahoo.com
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
April 21, 2023 | markets.businessinsider.com
SELLAS Life Sciences Group (SLS) Gets a Buy from Maxim Group
April 21, 2023 | americanbankingnews.com
Solaris Resources (CVE:SLS) Stock Rating Reaffirmed by National Bank Financial
April 18, 2023 | finance.yahoo.com
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
March 24, 2023 | americanbankingnews.com
Cantor Fitzgerald Comments on SELLAS Life Sciences Group, Inc.'s FY2023 Earnings (NASDAQ:SLS)
March 18, 2023 | markets.businessinsider.com
Maxim Group Remains a Buy on SELLAS Life Sciences Group (SLS)
March 17, 2023 | finanznachrichten.de
SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
March 16, 2023 | msn.com
SELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-line
March 16, 2023 | finance.yahoo.com
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
March 7, 2023 | finance.yahoo.com
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
February 24, 2023 | msn.com
Why Sellas Life Sciences Shares Are Nosediving
February 24, 2023 | finance.yahoo.com
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
February 24, 2023 | finance.yahoo.com
Sellas Life Sciences raises $20 million from public offering of stock, warrants
February 24, 2023 | finance.yahoo.com
Sellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offering
February 5, 2023 | finance.yahoo.com
Here's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Situation
January 19, 2023 | finance.yahoo.com
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
January 5, 2023 | finance.yahoo.com
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
See More Headlines

SLS Price History

SLS Company Calendar

Last Earnings
3/30/2023
Today
6/02/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLS
CUSIP
N/A
CIK
1390478
Web
www.sellaslifesciences.com
Phone
(646) 200-5278
Fax
441-400-2875
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+309.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,300,000.00
Net Margins
N/A
Pretax Margin
-4,130.10%
Return on Equity
-287.10%
Return on Assets
-131.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.68
Quick Ratio
1.68

Sales & Book Value

Annual Sales
$1 million
Price / Sales
48.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.46 per share
Price / Book
3.72

Miscellaneous

Outstanding Shares
28,350,000
Free Float
28,036,000
Market Cap
$48.48 million
Optionable
Not Optionable
Beta
2.24

Key Executives

  • Angelos M. Stergiou
    President, Chief Executive Officer & Director
  • John T. Burns
    Chief Financial Officer & Accounting Officer, SVP
  • Dragan Cicic
    Senior Vice President-Clinical Development
  • Barbara A. Wood
    Secretary, Executive VP & General Counsel
  • Robert M. Francomano
    Chief Commercial Officer & Senior Vice President

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SLS Stock - Frequently Asked Questions

Should I buy or sell SELLAS Life Sciences Group stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLS shares.
View SLS analyst ratings or view top-rated stocks.

What is SELLAS Life Sciences Group's stock price forecast for 2023?

2 analysts have issued 1-year price objectives for SELLAS Life Sciences Group's stock. Their SLS share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 309.4% from the stock's current price.
View analysts price targets for SLS or view top-rated stocks among Wall Street analysts.

How have SLS shares performed in 2023?

SELLAS Life Sciences Group's stock was trading at $6.15 at the beginning of the year. Since then, SLS stock has decreased by 72.2% and is now trading at $1.71.
View the best growth stocks for 2023 here.

When is SELLAS Life Sciences Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SLS earnings forecast.

How were SELLAS Life Sciences Group's earnings last quarter?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.15) earnings per share (EPS) for the quarter.

When did SELLAS Life Sciences Group's stock split?

SELLAS Life Sciences Group shares reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What is SELLAS Life Sciences Group's stock symbol?

SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."

Who are SELLAS Life Sciences Group's major shareholders?

SELLAS Life Sciences Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Highbridge Capital Management LLC (6.37%), Equitable Holdings Inc. (0.46%), State Street Corp (0.34%), Dimensional Fund Advisors LP (0.11%) and Susquehanna International Group LLP (0.00%).
View institutional ownership trends.

How do I buy shares of SELLAS Life Sciences Group?

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SELLAS Life Sciences Group's stock price today?

One share of SLS stock can currently be purchased for approximately $1.71.

How much money does SELLAS Life Sciences Group make?

SELLAS Life Sciences Group (NASDAQ:SLS) has a market capitalization of $48.48 million and generates $1 million in revenue each year. The company earns $-41,300,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How can I contact SELLAS Life Sciences Group?

SELLAS Life Sciences Group's mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The official website for the company is www.sellaslifesciences.com. The company can be reached via phone at (646) 200-5278, via email at ir@sellaslife.com, or via fax at 441-400-2875.

This page (NASDAQ:SLS) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -